title: Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma.
abstract: BACKGROUND
  The human multi-drug resistance gene (MDR1), which encodes the major trans-membrane transporter P-glycoprotein (P-gp), was found to be associated with susceptibility to cancer and response to chemotherapy. The C3435T Polymorphism of MDR1 gene was correlated with expression levels and functions of P-gp. Here, we studied the association between MDR1 C3435T polymorphism and susceptibility to Hodgkin lymphoma (HL) and patient's response to ABVD chemotherapy regimen.
  
  
  METHODS
  a total of 130 paraffin embedded tissue samples collected from HL patients were analyzed to identify the C3435T polymorphism. As a control group, 120 healthy subjects were enrolled in the study. The C3435T Polymorphism was genotyped by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method. Data analysis was carried out using the statistical package SPSS version 17 to compute all descriptive statistics. Chi-square and Fisher exact tests were used to evaluate the genotype distribution and allele frequencies of the studied polymorphism.
  
  
  RESULTS
  these studies revealed that the frequency of T allele was significantly higher in HL patients compared to the controls (P < 0.05). In addition, the frequency of CT and TT genotypes were also significantly higher in HL patients compared to the controls (P < 0.05). No association between C3435T polymorphism and response to ABVD was detected among HL patients (P > 0.05).
  
  
  CONCLUSIONS
  these results suggest that MDR1 C3435T polymorphism might play a role in HL occurrence; however this polymorphism is not correlated with the clinical response to ABVD.
authors.affiliation: Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan. nizarm@just.edu.jo
authors.forename: Nizar M
authors.initials: NM
authors.lastname: Mhaidat
authors.forename: Osama Y
authors.initials: OY
authors.lastname: Alshogran
authors.forename: Omar F
authors.initials: OF
authors.lastname: Khabour
authors.forename: Karem H
authors.initials: KH
authors.lastname: Alzoubi
authors.forename: Ismail I
authors.initials: II
authors.lastname: Matalka
authors.forename: William J
authors.initials: WJ
authors.lastname: Haddadin
authors.forename: Ibraheem O
authors.initials: IO
authors.lastname: Mahasneh
authors.forename: Ahmad N
authors.initials: AN
authors.lastname: Aldaher
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D005838:Genotype; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008297:Male; D053589:Nuchal Cord; D011237:Predictive Value of Tests; D012307:Risk Factors; D055815:Young Adult
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1